12 results about "Gastric Diseases" patented technology

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

The application discloses a kind of biological hybrid micro machine population oral delivery system of imitating Helicobacter pylori survival mechanism, belong to oral stomach medicine delivery technical field.The system is by active power module (flagellum driven chlamydomonas reinhardtii), environmental regulation module (acid urease modified on algal surface) and multifunctional load module (macrophage membrane wrapped drug-loaded nanoparticles) synergistic assembly through polydopamine (PDA) spatial conformation control layer is formed.Active power module utilizes self-movement ability to penetrate mucus barrier and extend intracavity retention time to 12 hours or more;Environmental regulation module produces local alkalization effect by catalyzing urea hydrolysis, provides chemical shield for system in extremely acid environment of pH 1.0-3.0, protects active power module from gastric acid inactivation;Multifunctional load module is accurately delivered to gastric epithelial cells by inflammation targeting effect, such as CRISPR / Cas9 biological macromolecule, and realizes up to 31.8% in-vivo gene editing efficiency.The application provides a non-invasive, modular active delivery platform for the precise treatment of gastric diseases such as gastritis through the synergistic effect of physical penetration, metabolic reprogramming and gene intervention.

The invention discloses an application of food-grade sodium carbonate in preparation of a medicine for regulating the acid-base balance of human tissues. The food-grade sodium carbonate conforming to the national food safety standard (GB1886.1) is used as a unique effective component and is dissolved in water to prepare sodium carbonate aqueous solutions with different concentrations, and acid metabolites accumulated in human tissues in local and whole body levels and in human tissues are treated by multiple administration routes such as external use and oral administration. The normal acid-base microenvironment of the tissue is recovered. Wherein the mass concentration of the external preparation is 0.05%-10%, and the mass concentration of the oral preparation is 0.1%-1.5%. The traditional Chinese medicine composition can be used for preventing and / or treating cancers and malignant tumors, stomach diseases related to hyperacidity, femoral head necrosis, muscle strain, frostbite and various diseases taking acid-base imbalance as a common pathological basis. The raw materials are wide in source, low in price and high in safety, the preparation process is simple, the administration scheme is systematic and complete, a single or combined administration route can be flexibly selected according to the specific condition of a patient, and individualized treatment is achieved.

This invention discloses a high-load XOR tumor-targeting therapy nanoplatform based on ROS activity and its applications, belonging to the field of nanobiomaterials. This high-load XOR tumor-targeting therapy nanoplatform, using a zeolite imidazole framework-8 (ZIF-8) as a carrier, contains xanthine oxidoreductase (XOR) with cellular enzymatic activity. It possesses the ability to target tumor cells and induce intracellular reactive oxygen species (ROS), leading to tumor cell death. Induction of intracellular ROS in tumor macrophages (TAMs) also supports the differentiation of macrophages into M1 types. ROS-induced apoptosis in tumor cells produces a series of tumor-associated antigens, which further promotes the infiltration and activation of macrophages in the tumor microenvironment. This, in turn, leads to increased infiltration of CD8+ T cells in the tumor, whose cytokine profile shows cytotoxic effects, indicating successful induction of an adaptive anti-tumor response. This novel nanomaterial offers a promising new strategy for the immunotherapy of gastric diseases.

The application discloses a short-wave ultraviolet irradiation-based stomach disease treatment instrument, and belongs to the technical field of medical equipment.The application comprises a treatment instrument main body, a main pipe body, a probe end, an ultraviolet emission end and a treatment control module for controlling the treatment instrument main body; the modular design of the treatment instrument main body and the combination with the ultraviolet emission end improve the clinical operability and treatment effect, the combination with the rotary toothed disc driving mechanism enables the ultraviolet emission end to realize all-around twisting, covers the stomach area, the light-transmitting layer blocks infrared radiation while ensuring the ultraviolet transmittance, reduces the thermal stimulation on the stomach tissue, and enables medical staff to observe the irradiation effect in real time, realizes visual treatment, the treatment control module realizes the precision and intelligence of stomach disease treatment through a multi-unit cooperative architecture, generates a personalized scheme based on the disease type and the lesion position, monitors the physiological indexes of patients in real time and dynamically adjusts the treatment parameters, and improves the treatment safety and effectiveness.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

Recombinant blood group antigen-binding adhesin (BabA) can be used in a composition to raise humoral immune response i.e. antibodies, that target conserved structural epitopes in the fucosylated blood group antigen Lewis b (Leb) antigen binding domain in the blood group antigen-binding adhesin (BabA). Such broadly Leb-blocking antibodies can reduce the gastric mucosal attachment of Helicobacter pylori (H. pylori) to human gastric mucosa. This approach can be used for preventing and / or alleviating gastric disease in a subject diagnosed with H. pylori infection, said gastric disease chosen from gastroesophageal reflux disease, chronic active gastritis, peptic ulcer diseases, gastric ulcer disease, gastric cancer gastritis and gastric cancer, in particular gastric cancer. It also becomes possible to identify subjects that carry BabA positive H. pylori infections and subjects that are at risk of developing severe gastric disease, such as peptic ulcer diseases, gastric ulcer disease, gastritis with metaplasia and gastric cancer.

The invention provides a nucleic acid fragment of helicobacter pylori (HP) which is pathogenic to gastric cancer and application of the nucleic acid fragment of the helicobacter pylori (HP). In the invention, a novel gastric cancer treatment method is explored based on an HP pathogenic mechanism, a nucleic acid fragment (EC-HP-Fs) causing gastric cancer in HP is determined, and the nucleic acid fragment can participate in an HP-induced gastric cancer process through epigenetic regulation of expression of a host gene to promote the gastric cancer process, and can be used as a new target to treat gastric cancer. The invention also provides nucleic acid inhibitors for targeted modulation. The invention provides a new target for clinical treatment and detection of infectious stomach diseases caused by HP or HP.

The invention relates to the technical field of gastric electricity detection instruments, in particular to a wearable multi-channel gastric electricity acquisition system which adopts a modular design of a gastric electricity acquisition electrode bandage, a detection host and an information terminal. The detection host can be assembled on a stomach electricity collection electrode bandage and worn on a subject for use, multi-channel stomach electricity signal collection is executed through the stomach electricity collection electrode bandage, and the detection host integrates skin contact impedance detection and analog-to-digital conversion functions. Under the condition of ensuring that the skin contact impedance is in a normal state, each path of converted stomach electricity digital signal is sent to an information terminal; and the information terminal interacts with the detection host to send an operation control instruction, and performs processing according to each path of fed-back stomach electricity digital signal to obtain a stomach electricity state detection result of the subject. According to the invention, a subject can wear the device to detect the gastric function state, the use threshold is effectively reduced, and the device is suitable for families, communities and mobile medical scenes and is more beneficial to early screening and long-term management of gastric diseases.

The invention discloses a rapidly-dissolved finasteride tablet and a production method thereof, and relates to the technical field of medicine preparation. According to the invention, finasteride is loaded in carboxylated mesoporous silica, so that drug molecules of finasteride are dispersed from a crystalline state to an amorphous state, the dissolution rate is improved, carboxyl maintains a non-ionized state in a gastric juice environment, stimulation of drugs in a gastric acid environment is reduced, carboxyl is ionized in an intestinal solution, and the dissolution rate of the drugs is increased. The quick release of the medicine can be realized; according to the invention, a modified polymer emulsion is also prepared as a material of a coating solution, by utilizing the characteristics of the coating solution, the tablet is insoluble in a gastric acid environment and dissolved in an intestinal juice environment, the irritation to patients with stomach diseases is reduced, and the intestinal absorption area is relatively large, so that the absorption rate of the medicine is improved, and the bioavailability is improved.

This invention relates to an oral microemulsion containing elemene, its preparation method, and its uses. The microemulsion has a simple formulation, high drug loading capacity, good stability, and a simple preparation process, making it suitable for the prevention and treatment of gastric diseases, especially gastric cancer.

The invention provides application of a genetic regulation molecular axis in gastric lesion evolution discrimination and drug screening, and belongs to the technical field of biological medicines. The specific dynamic expression track of the lnc517368 / miR-203b-3p / SMAD2 axis in gastric lesion evolution is disclosed and defined for the first time, and brand new molecular basis and objective standard are provided for stage discrimination of gastric diseases. Meanwhile, an intervention strategy taking the axis as a target is defined, and a reliable screening and evaluation system is established for developing drugs for blocking or reversing the progress of stomach lesion. And by taking a turbid-dissolving and detoxifying formula as an example, reversible intervention of a disease evolution trajectory can be realized by adjusting the shaft, so that the method not only has important scientific theoretical value, but also shows wide conversion and application prospects in the aspects of disease diagnosis, drug research and development, clinical treatment strategy formulation and the like.